Alpha Centric Advisors LLC Celldex Therapeutics, Inc. Transaction History
Alpha Centric Advisors LLC
- $118 Million
- Q3 2024
A detailed history of Alpha Centric Advisors LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 30,000 shares of CLDX stock, worth $730,500. This represents 0.86% of its overall portfolio holdings.
Number of Shares
30,000
Previous 47,500
36.84%
Holding current value
$730,500
Previous $1.76 Million
42.0%
% of portfolio
0.86%
Previous 1.45%
Shares
7 transactions
Others Institutions Holding CLDX
# of Institutions
206Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$225 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$114 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$94.2 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$84.2 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$81.1 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.14B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...